Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

438.65 +4.27 (+0.98%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
61 62 Next >
My 2 Favorite Growth Stocks to Buy Hand Over Fist in November
The sky's the limit for these stocks. 
Via The Motley Fool
Vertex Pharmaceuticals (VRTX) Q3 2024 Earnings Call Transcript
VRTX earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Vertex Pharmaceuticals Beats Third-Quarter Estimates As Pain Treatment Looms
Vertex Pharmaceuticals beat third-quarter expectations on Monday. The company also raised its sales outlook. 
Via Investor's Business Daily
Vertex Reports Third Quarter 2024 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Volatility Hits Large Cap Biopharma: Active Rebalancing May Be Required
A bit of earnings and election jitters roiled the market last week reordering the leaderboard in biopharma stocks. 
Via Talk Markets
Looking Into Vertex Pharmaceuticals's Recent Short Interest
Via Benzinga
Market Whales and Their Recent Bets on VRTX Options
Via Benzinga
Wall Street Struggles Ahead Of Election Day, Energy Sector Outperforms, Solar Stocks Rise: What's Driving Markets Monday?
The U.S. stock market struggled to gain momentum on Monday as investors remained cautious ahead of Election Day on Tuesday. 
Via Benzinga
Jim Cramer Says Vertex Doing 'Lord's Work': Can Q3 Earnings Outshine Bearish Charts?
VRTX to report Q3 earnings, expected EPS $4.14 and $2.72B in revenue. Cramer calls it a buy, analysts see 22% upside. Stock faces bearish trend. 
Via Benzinga
Thinking of Buying CRISPR Therapeutics Stock? Watch These 2 Key Numbers
It won't be able to be profitable without hitting its targets for both of these figures. 
Via The Motley Fool
As Stock Market Awaits Election, Palantir, S&P 500 Nuke Leaders Report
Amid the election, and a Fed rate vote, earnings season roars ahead. 
Via Investor's Business Daily
Topics Economy Stocks
Exposures Interest Rates US Equities
Jim Cramer: This Financial Stock Is 'One Of The Most Consistent, Great Companies'
Mad Money's Jim Cramer recommends buying T. Rowe Price Group. "I think it's such a great company," he added. 
Via Benzinga
Vertex to Participate in Upcoming November Investor Conferences
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 5 Years
Via Benzinga
These 10 Stocks Were The Best S&P 500 Performers In 2017 When Trump Was President: Will History Repeat Itself?
A look back at the top 10 S&P 500 performing stocks in 2017 under Donald Trump's first year as president and what it could mean for his re-election efforts. 
Via Benzinga
Topics Government Stocks
Exposures Political US Equities
12 High-Growth Stocks That Could Deliver Parabolic Returns
These 12 innovative companies could deliver exponential returns over the next quarter century. 
Via The Motley Fool
Vertex Provides Updates on Multiple Kidney Programs at the American Society of Nephrology (ASN) Annual Kidney Week Congress
From Vertex Pharmaceuticals Incorporated
Via Business Wire
The Smartest Growth Stock to Buy With $500 Right Now
This stock might not be available for under $500 for long. 
Via The Motley Fool
Vertex Pharmaceuticals Just Found Its Newest Blockbuster Drug. A $41 Billion Market Awaits
Its latest report of clinical data suggests it has a winner on its hands. 
Via The Motley Fool
Why We Buy Stocks
Is fear of missing out (FOMO) controlling your portfolio? 
Via The Motley Fool
Prediction: These 2 Stocks Will Beat the S&P 500 Through 2030
There's no need to change a winning formula. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Vertex to Present Phase 3 Data Highlighting Suzetrigine’s Potential as a First-in-Class, Highly Selective Pain Signal Inhibitor at the American Society of Anesthesiologists Annual Meeting
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (19 Ratings)
Via Benzinga
Here's How Much $1000 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth Today
Via Benzinga
Got $1,000? 2 Magnificent Growth Stocks to Buy and Hold Forever
These profitable companies are facing long-term growth runways. 
Via The Motley Fool
3 No-Brainer Growth Stocks to Buy in October
These stocks look like slam-dunk picks for growth investors. 
Via The Motley Fool
Vertex to Announce Third Quarter 2024 Financial Results on November 4th
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients
The Biden administration's proposed Medicare $2 Drug List Model aims to provide low-cost generic drugs for seniors and people with disabilities, with copayments capped at $2 per month for essential... 
Via Benzinga
2 Biotech Stocks to Buy Hand Over Fist in October
These longtime leading biotech stocks still have plenty of upside ahead. 
Via The Motley Fool
Cathie Wood's Ark Invest Trades: Bets $14M On Amazon Shares — Dumps Robinhood Stock Worth $36M, Embraces Coinbase And Meta
Cathie Wood's Ark Invest made significant trades in Amazon.com Inc (NASDAQ: AMZN), Robinhood Markets Inc (NASDAQ: HOOD), and Coinbase Global Inc (NASDAQ: COIN) on Tuesday Oct 8, 2024. 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
61 62 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS